NCT05507879 is a clinical trial of Biospecimen Collection in Breast Carcinoma, sponsored by Mayo Clinic.

Who is sponsoring NCT05507879?

NCT05507879 is sponsored by Mayo Clinic.

What drugs are being tested in NCT05507879?

Interventions in NCT05507879: Biospecimen Collection, Electronic Medical Record.

What condition does NCT05507879 study?

NCT05507879 studies Breast Carcinoma, Cardiomyopathy, Congestive Heart Failure.

Is NCT05507879 still recruiting?

NCT05507879 is currently recruiting now. Last updated 10 February 2026.

Last reviewed 2026-02-10 · How we verify

NCT05507879

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer

Recruiting now Last updated 10 February 2026

What this trial tests

trial testing Biospecimen Collection in Breast Carcinoma in 200 participants. Currently enrolling.

Timeline

26 September 2022

Primary endpoint
1 September 2026

1 September 2027

Quick facts

Lead sponsor	Mayo Clinic
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	26 September 2022
Primary completion	1 September 2026
Estimated completion	1 September 2027
Sites	2 locations across United States

Drugs / interventions tested

Biospecimen Collection — full drug profile →
Electronic Medical Record

Conditions studied

Breast Carcinoma — all drugs for Breast Carcinoma →
Cardiomyopathy — all drugs for Cardiomyopathy →
Congestive Heart Failure — all drugs for Congestive Heart Failure →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Breast Carcinoma or Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study examines TRPC6 in predicting and preventing chemotherapy related cardiac toxicity and heart failure in patients with breast cancer. Cardiac toxicity, changes in heart function is a well-recognized complication of certain cancer related therapies. Understanding these changes may allow early intervention against therapy-related cardiac toxicity and also identify novel therapeutic targets to protect patient long-term cardiac health. Studying samples of blood from patients with breast cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA), identify biomarkers related to cardiac toxicity, and prevent the development of therapy-induced cardiac toxicity in patients receiving chemotherapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

TRP Channels in Cancer: Signaling Mechanisms and Translational Approaches.
Marini M, Titiz M, Souza Monteiro de Araújo D, Geppetti P, et al · · 2023 · cited 39× · PMID 37892239 · DOI 10.3390/biom13101557
Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations.
Tetterton-Kellner J, Jensen BC, Nguyen J. · · 2024 · cited 20× · PMID 38901637 · DOI 10.1016/j.addr.2024.115361
TRP channels and cancer modulation: a voyage beyond metabolic reprogramming, oxidative stress and the advent of nanotechnologies in targeted therapy.
Giannaccari M, Florindi C, Bloise N, Moccia F, et al · · 2025 · cited 9× · PMID 40813985 · DOI 10.1186/s13046-025-03495-4
Physiological functions and pharmacological targeting of transient receptor potential channels.
Chubanov V, Grimm C, Hill K, Schaefer M, et al · · 2025 · PMID 41118703 · DOI 10.1016/j.pharmr.2025.100089

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

NCT07067138 — A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS- · NA · recruiting
NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
NCT07338721 — Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer? · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05507879 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 10 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05507879.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing